Overview

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

Status:
Completed

Trial end date:
2019-07-24

Target enrollment:

Participant gender:

Summary

This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma concentrations on the heart rate-corrected QT interval (QTc).

Phase:

Phase 1

Details

Lead Sponsor:

Entasis Therapeutics

Treatments:

Moxifloxacin
Norgestimate, ethinyl estradiol drug combination